• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 奥密克戎亚变种逐渐适应宿主细胞进入机制改变的人类细胞。

SARS-CoV-2 Omicron subvariants progressively adapt to human cells with altered host cell entry.

机构信息

Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.

Department of Emerging Infectious Diseases, National Research Center for the Control and Prevention of Infectious Diseases (CCPID), Nagasaki University, Nagasaki, Japan.

出版信息

mSphere. 2024 Sep 25;9(9):e0033824. doi: 10.1128/msphere.00338-24. Epub 2024 Aug 27.

DOI:10.1128/msphere.00338-24
PMID:39191389
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11423564/
Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant exhibits high transmissibility with a strong immune escape ability and causes frequent large-scale global infections by producing predominant subvariants. Here, using human upper/lower airway and intestinal cells, we examined the previously dominant BA.1-BA.5 and BA.2.75 subvariants, together with the recently emerged XBB/BQ lineages, in comparison to the former Delta variant. We observed a tendency for each virus to demonstrate higher growth capability than the previously dominant subvariants. Unlike human bronchial and intestinal cells, nasal epithelial cells accommodated the efficient entry of certain Omicron subvariants, similar to the Delta variant. In contrast to the Delta's reliance on cell-surface transmembrane protease serine 2, all tested Omicron variants depended on endosomal cathepsin L. Moreover, S1/S2 cleavage of early Omicron spikes was less efficient, whereas recent viruses exhibit improved cleavage efficacy. Our results show that the Omicron variant progressively adapts to human cells through continuous endosome-mediated host cell entry.IMPORTANCESARS-CoV-2, the causative agent of coronavirus disease 2019, has evolved into a number of variants/subvariants, which have generated multiple global waves of infection. In order to monitor/predict virological features of emerging variants and determine appropriate strategies for anti-viral development, understanding conserved or altered features of evolving SARS-CoV-2 is important. In this study, we addressed previously or recently predominant Omicron subvariants and demonstrated the gradual adaptation to human cells. The host cell entry route, which was altered from the former Delta variant, was conserved among all tested Omicron subvariants. Collectively, this study revealed both changing and maintained features of SARS-CoV-2 during the Omicron variant evolution.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的奥密克戎变体具有很强的传染性和免疫逃逸能力,通过产生主要的亚变体频繁引起全球大规模感染。在这里,我们使用人上/下呼吸道和肠道细胞,与之前的德尔塔变体相比,研究了之前占主导地位的 BA.1-BA.5 和 BA.2.75 亚变体,以及最近出现的 XBB/BQ 谱系。我们观察到每种病毒的生长能力都有比之前占主导地位的亚变体更高的趋势。与人类支气管和肠道细胞不同,鼻上皮细胞允许某些奥密克戎亚变体的有效进入,类似于德尔塔变体。与德尔塔依赖细胞表面跨膜丝氨酸蛋白酶 2 不同,所有测试的奥密克戎变体都依赖内体组织蛋白酶 L。此外,早期奥密克戎刺突的 S1/S2 裂解效率较低,而最近的病毒则表现出更好的裂解效率。我们的结果表明,奥密克戎变体通过持续的内体介导的宿主细胞进入逐渐适应人类细胞。

重要提示

导致 2019 年冠状病毒病的严重急性呼吸综合征冠状病毒 2 已进化成多种变体/亚变体,这些变体引发了多波全球感染。为了监测/预测新兴变体的病毒学特征并确定抗病毒发展的适当策略,了解不断进化的 SARS-CoV-2 的保守或改变特征很重要。在这项研究中,我们研究了之前或最近占主导地位的奥密克戎亚变体,并证明了它们逐渐适应人类细胞。宿主细胞进入途径与之前的德尔塔变体不同,但在所有测试的奥密克戎亚变体中都得到了保留。总的来说,这项研究揭示了 SARS-CoV-2 在奥密克戎变体进化过程中不断变化和保持的特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3360/11423564/4243615fb476/msphere.00338-24.f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3360/11423564/e88287ceaa32/msphere.00338-24.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3360/11423564/e32686b6c5ed/msphere.00338-24.f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3360/11423564/00d2a2d1091f/msphere.00338-24.f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3360/11423564/6b7b550e5c10/msphere.00338-24.f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3360/11423564/7b78096a8949/msphere.00338-24.f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3360/11423564/4243615fb476/msphere.00338-24.f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3360/11423564/e88287ceaa32/msphere.00338-24.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3360/11423564/e32686b6c5ed/msphere.00338-24.f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3360/11423564/00d2a2d1091f/msphere.00338-24.f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3360/11423564/6b7b550e5c10/msphere.00338-24.f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3360/11423564/7b78096a8949/msphere.00338-24.f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3360/11423564/4243615fb476/msphere.00338-24.f006.jpg

相似文献

1
SARS-CoV-2 Omicron subvariants progressively adapt to human cells with altered host cell entry.SARS-CoV-2 奥密克戎亚变种逐渐适应宿主细胞进入机制改变的人类细胞。
mSphere. 2024 Sep 25;9(9):e0033824. doi: 10.1128/msphere.00338-24. Epub 2024 Aug 27.
2
Differentiating Cell Entry Potentials of SARS-CoV-2 Omicron Subvariants on Human Lung Epithelium Cells.区分 SARS-CoV-2 奥密克戎亚变种对人肺上皮细胞的细胞进入潜力。
Viruses. 2024 Mar 1;16(3):391. doi: 10.3390/v16030391.
3
Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission.温度依赖性的奥密克戎亚变种的 Spike-ACE2 相互作用与病毒传播有关。
mBio. 2024 Aug 14;15(8):e0090724. doi: 10.1128/mbio.00907-24. Epub 2024 Jul 2.
4
SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models.SARS-CoV-2 奥密克戎变体的进入是通过人类气道和肠类器官模型中的 II 型跨膜丝氨酸蛋白酶介导的。
J Virol. 2023 Aug 31;97(8):e0085123. doi: 10.1128/jvi.00851-23. Epub 2023 Aug 9.
5
SARS-CoV-2 Omicron BA.1 Variant Infection of Human Colon Epithelial Cells.严重急性呼吸综合征冠状病毒2型奥密克戎BA.1变异株对人结肠上皮细胞的感染
Viruses. 2024 Apr 19;16(4):634. doi: 10.3390/v16040634.
6
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.新冠病毒奥密克戎改变 TMPRSS2 的使用方式影响其感染性和融合性。
Nature. 2022 Mar;603(7902):706-714. doi: 10.1038/s41586-022-04474-x. Epub 2022 Feb 1.
7
Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.刺突蛋白结构特征、决定病毒进入宿主细胞的物种特异性血管紧张素转换酶 2 残基,以及奥密克戎 BA.1、BA.1.1、BA.2 和 BA.3 变异株的抗体中和逃逸。
J Virol. 2022 Sep 14;96(17):e0114022. doi: 10.1128/jvi.01140-22. Epub 2022 Aug 24.
8
Clinical Isolates of Human Coronavirus 229E Bypass the Endosome for Cell Entry.人冠状病毒229E的临床分离株通过绕过内体进入细胞。
J Virol. 2016 Dec 16;91(1). doi: 10.1128/JVI.01387-16. Print 2017 Jan 1.
9
Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals.纳米摩尔级抗 SARS-CoV-2 奥密克戎活性的宿主靶向 TMPRSS2 抑制剂 N-0385 及其与直接作用抗病毒药物的协同作用。
Antiviral Res. 2024 May;225:105869. doi: 10.1016/j.antiviral.2024.105869. Epub 2024 Mar 26.
10
Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants.奥密克戎亚变体低融合性和高度依赖内体进入的决定因素和机制。
mBio. 2023 Feb 28;14(1):e0317622. doi: 10.1128/mbio.03176-22. Epub 2023 Jan 10.

引用本文的文献

1
Host susceptibilities and entry processes of SARS-CoV-2 Omicron variants using pseudotyped viruses carrying spike protein.使用携带刺突蛋白的假型病毒研究SARS-CoV-2奥密克戎变体的宿主易感性和进入过程。
BMC Vet Res. 2025 May 27;21(1):377. doi: 10.1186/s12917-025-04822-9.
2
Identification of a Novel Antiviral Lectin against SARS-CoV-2 Omicron Variant from Shiitake-Mushroom-Derived Vesicle-like Nanoparticles.从香菇衍生的囊泡样纳米颗粒中鉴定出一种针对 SARS-CoV-2 奥密克戎变异株的新型抗病毒凝集素。
Viruses. 2024 Sep 30;16(10):1546. doi: 10.3390/v16101546.
3
Cholesterol and Cholesterol-Lowering Medications in COVID-19-An Unresolved Matter.

本文引用的文献

1
Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo.在体外和体内对 SARS-CoV-2 EG.5.1 临床分离株进行鉴定。
Cell Rep. 2023 Dec 26;42(12):113580. doi: 10.1016/j.celrep.2023.113580. Epub 2023 Dec 15.
2
Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎BA.2.75亚谱系不断演变的抗体逃逸和受体亲和力
iScience. 2023 Oct 18;26(11):108254. doi: 10.1016/j.isci.2023.108254. eCollection 2023 Nov 17.
3
Evolution of the SARS-CoV-2 Omicron spike.
胆固醇和降胆固醇药物在 COVID-19 中的作用——一个悬而未决的问题。
Int J Mol Sci. 2024 Sep 29;25(19):10489. doi: 10.3390/ijms251910489.
奥密克戎变异株刺突蛋白的进化。
Cell Rep. 2023 Dec 26;42(12):113444. doi: 10.1016/j.celrep.2023.113444. Epub 2023 Nov 18.
4
SARS-CoV-2 evolution in the Omicron era.奥密克戎时代的 SARS-CoV-2 进化。
Nat Microbiol. 2023 Nov;8(11):1952-1959. doi: 10.1038/s41564-023-01504-w. Epub 2023 Oct 16.
5
Direct infection of SARS-CoV-2 in human iPSC-derived 3D cardiac organoids recapitulates COVID-19 myocarditis.SARS-CoV-2 直接感染人诱导多能干细胞衍生的 3D 心脏类器官可再现 COVID-19 心肌炎。
Virol Sin. 2023 Dec;38(6):971-974. doi: 10.1016/j.virs.2023.09.005. Epub 2023 Sep 30.
6
Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron variants in mice and hamsters.在小鼠和仓鼠中对 SARS-CoV-2 BA.5.5 和 BQ.1.1 奥密克戎变体的特征描述。
J Virol. 2023 Sep 28;97(9):e0062823. doi: 10.1128/jvi.00628-23. Epub 2023 Sep 7.
7
The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5.主要 SARS-CoV-2 奥密克戎亚谱系 BA.1、BA.2 和 BA.5 的病毒适应性和内在致病性。
EBioMedicine. 2023 Sep;95:104753. doi: 10.1016/j.ebiom.2023.104753. Epub 2023 Aug 12.
8
Comparison of genome replication fidelity between SARS-CoV-2 and influenza A virus in cell culture.细胞培养中 SARS-CoV-2 和流感 A 病毒基因组复制保真度的比较。
Sci Rep. 2023 Aug 11;13(1):13105. doi: 10.1038/s41598-023-40463-4.
9
Transmission and re-infection of Omicron variant XBB.1.5 in hamsters.仓鼠中奥密克戎变异株 XBB.1.5 的传播和再感染。
EBioMedicine. 2023 Jul;93:104677. doi: 10.1016/j.ebiom.2023.104677. Epub 2023 Jun 21.
10
Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron Lineages - United States, January 2022-May 2023.SARS-CoV-2 变异株的基因组监测:奥密克戎谱系的传播-美国,2022 年 1 月-2023 年 5 月。
MMWR Morb Mortal Wkly Rep. 2023 Jun 16;72(24):651-656. doi: 10.15585/mmwr.mm7224a2.